In this issue:
Health-related QOL with lenalidomide in lower-risk MDS
First-line danazol acceptable for SCT-ineligible MDS
Eltrombopag for advanced MDS/AML with severe thrombocytopenia
Consolidation RT in advanced Hodgkin’s lymphoma with complete metabolic response
Australasia has highest incidence of leukaemia
Switching to nilotinib in chronic-phase CML after major MR to imatinib
Nilotinib after first-line imatinib in real-life chronic-phase CML
Single-agent ibrutinib in relapsed/refractory follicular lymphoma
All-trans retinoic acid + anthracyclinebased regimens for older APL
Please login below to download this issue (PDF)